GeoVax shares rise on NIH vaccine deal

/ / News

Shares of GeoVax Labs Inc. were up 12.8% in trading on Monday after the company announced a patent and material licensing deal with the National Institutes of Health for COVID-19 vaccine development. As part of the agreement, the clinical-stage company said it will get access to patent rights in the virus’ spike protein and has non-exclusive rights to develop a COVID-19 vaccine. No financial terms were disclosed. GeoVax said it has four COVID-19 vaccine candidates in development, though none have moved past preclinical studies into phased testing in humans. GeoVax’s stock has tumbled 70.3% so far this year, compared with the S&P 500 is up 7.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.